At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HRMY Harmony Biosciences Holdings, Inc.
Trading 11-04 14:27:32 EST
34.69
-2.33
-6.29%
High35.86Low32.61Vol1.69M
Open34.50D1 Closing37.02Amplitude8.78%
Mkt Cap2.02BTradable Cap1.81BTotal Shares58.24M
T/O57.66MT/O Rate3.24%Tradable Shares52.10M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Harmony Biosciences Holdings, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary
Reuters  ·  11-04 22:32
Harmony Biosciences Holdings, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary
Harmony Biosciences Shares Down 5.7% Premarket After Q3 Revenue, Pretax Profit Miss
THOMSON REUTERS  ·  11-04 20:47
Harmony Biosciences Shares Down 5.7% Premarket After Q3 Revenue, Pretax Profit Miss
Earnings Flash (HRMY) Harmony Biosciences Posts Q3 EPS $0.81, vs. FactSet Est of $1.09
MT Newswires Live  ·  11-04 20:39
Earnings Flash (HRMY) Harmony Biosciences Posts Q3 EPS $0.81, vs. FactSet Est of $1.09
Harmony Biosciences Q3 Net Income Falls 5% Year over Year to USD 48.2 Million
Reuters  ·  11-04 20:36
Harmony Biosciences Q3 Net Income Falls 5% Year over Year to USD 48.2 Million
Harmony Biosciences Q3 EPS $0.81 Misses $1.10 Estimate, Sales $268.917M Miss $273.078M Estimate
Benzinga Earnings  ·  11-04 20:33
Harmony Biosciences Q3 EPS $0.81 Misses $1.10 Estimate, Sales $268.917M Miss $273.078M Estimate
Harmony Biosciences Names Peter Anastasiou President and CEO Effective Jan. 1, 2027
Reuters  ·  11-04 20:33
Harmony Biosciences Names Peter Anastasiou President and CEO Effective Jan. 1, 2027
Harmony Biosciences - Pitolisant Hd Phase 3 Topline Data Expected in 2027; Target Pdufa Date in 2028
THOMSON REUTERS  ·  11-04 20:30
Harmony Biosciences - Pitolisant Hd Phase 3 Topline Data Expected in 2027; Target Pdufa Date in 2028
Harmony Biosciences Q3 Operating Income USD 54.197 Million
THOMSON REUTERS  ·  11-04 20:30
Harmony Biosciences Q3 Operating Income USD 54.197 Million
Harmony Biosciences - Pitolisant Gr Nda Under FDA Review; Pdufa Date April 1, 2027
THOMSON REUTERS  ·  11-04 20:30
Harmony Biosciences - Pitolisant Gr Nda Under FDA Review; Pdufa Date April 1, 2027
Harmony Biosciences Q3 Gross Profit USD 188.231 Million
THOMSON REUTERS  ·  11-04 20:30
Harmony Biosciences Q3 Gross Profit USD 188.231 Million
Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More than $1 Billion Wakix Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
THOMSON REUTERS  ·  11-04 20:30
Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More than $1 Billion Wakix Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
Harmony Biosciences Sets Incoming CEO Peter Anastasiou's Annual Base Salary at $725,000
Reuters  ·  10-31
Harmony Biosciences Sets Incoming CEO Peter Anastasiou's Annual Base Salary at $725,000
Earning Preview: Harmony Biosciences Holdings, Inc. this quarter’s revenue is expected to increase by 22.08%, and institutional views are cautiously positive
Earnings Agent  ·  10-28
Earning Preview: Harmony Biosciences Holdings, Inc. this quarter’s revenue is expected to increase by 22.08%, and institutional views are cautiously positive
Harmony Biosciences: Buy Rating Reiterated as Patent Strength and Clinical Catalysts Support Blockbuster WAKIX Profile; $55 Price Target Maintained
TIPRANKS  ·  10-27
Harmony Biosciences: Buy Rating Reiterated as Patent Strength and Clinical Catalysts Support Blockbuster WAKIX Profile; $55 Price Target Maintained
Revisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences
Dow Jones  ·  10-22
Revisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Zai Lab (ZLAB)
TIPRANKS  ·  10-19
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Zai Lab (ZLAB)
Harmony Biosciences Price Target Maintained with a $50.00/Share by Needham
Dow Jones  ·  10-19
Harmony Biosciences Price Target Maintained with a $50.00/Share by Needham
Mizuho positive on Harmony Biosciences CEO transition
TIPRANKS  ·  10-12
Mizuho positive on Harmony Biosciences CEO transition
Harmony Biosciences Price Target Maintained with a $50.00/Share by Needham
Dow Jones  ·  10-12
Harmony Biosciences Price Target Maintained with a $50.00/Share by Needham
US Stocks on the MOVE-Salesforce, Brown & Brown, IonQ, Harmony Biosciences
Reuters  ·  10-12
US Stocks on the MOVE-Salesforce, Brown & Brown, IonQ, Harmony Biosciences

Introduction

Company Name.
Harmony Biosciences Holdings, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Issue price:
--